How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide
Background. Tamoxifen has been shown to reduce the incidence of invasive breast cancer in women at higher risk. Translating these research results to clinical practice is challenging. Our objective was to develop and evaluate a decision-making guide and process that can be used in clinical practice to inform eligible women of chemoprevention with tamoxifen.
Methods. A decision guide explaining the benefits and risks of tamoxifen was developed with input from health care professionals and two focus groups of women both with and without cancer. Following consent, 51 eligible women presenting to a multi-disciplinary diagnostic facility for breast problems were given the decision guide/questionnaire to read, fill out and return by mail. Women with further questions or wanting to take tamoxifen were encouraged to re-contact their physicians.
Results. Atypia was seen in 60% of subjects. Median 5-year Gail risk was 3.7 (range 1.7–9.4). Only 6 (11.8% 95% CI = 2.9, 20.6%) women reported they would like to take tamoxifen while 6 (11.8% 95% CI = 2.9, 20.6%) remained uncertain.
Conclusion. We have developed a decision-making guide and process that is acceptable to providers and women to identify and inform women at higher risk of breast cancer with regard to chemoprevention with tamoxifen. Few women in this select group, when provided with a balanced decision guide, wished to pursue chemoprevention with tamoxifesn
Keywordsbreast cancer prevention decision guide increased breast cancer risk risk reduction tamoxifen
Fisher, B, Costantino, JP, Wickerham, DL, Redmond, CK, Kavanah, M, Cronin, WM, Vogel, V, Robidoux, A, Dimitrov, N, Atkins, J, Daly, M, Wieand, S, Tan-Chiu, E, Ford, L, Wolmark, N 1998Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst9013711388CrossRefPubMedGoogle Scholar
Levine, M, Moutquin, JM, Walton, R, Feightner, J 2001Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative’s Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast CancerCMAJ16416811690PubMedGoogle Scholar
U.S. Preventative Services Task Force: Chemoprevention of Breast Cancer.
http://www ahrq gov/clinic/3rduspstf/breastchemo/ 1–7–2002
Fisher, B 2000Re: tamoxifen prevention of breast cancer: an instance of the fingerpostJ Natl Cancer Inst92659660CrossRefPubMedGoogle Scholar
O’Connor, AM 1989Effects of framing and level of probability on patients’ preferences for cancer chemotherapyJ Clin Epidemiol42119126CrossRefPubMedGoogle Scholar
Slevin, ML, Stubbs, L, Plant, HJ, Wilson, P, Gregory, WM, Armes, PJ, Downer, SM 1990Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general publicBMJ30014581460PubMedGoogle Scholar
Port, ER, Montgomery, LL, Heerdt, AS, Borgen, PI 2001Patient reluctance toward tamoxifen use for breast cancer primary preventionAnn Surg Oncol8580585PubMedGoogle Scholar
Tchou, J, Hou, N, Rademaker, A, Jordan, VC, Morrow, M 2004Acceptance of tamoxifen chemoprevention by physicians and women at riskCancer10018001806CrossRefPubMedGoogle Scholar
Gail, MH, Brinton, LA, Byar, DP, Corle, DK, Green, SB, Schairer, C, Mulvihill, JJ 1989Projecting individualized probabilities of developing breast cancer for white females who are being examined annuallyJ Natl Cancer Inst8118791886PubMedGoogle Scholar
Woloshin, S, Schwartz, LM, Byram, S, Fischhoff, B, Welch, HG 2000A new scale for assessing perceptions of chance: a validation studyMed Decis Making20298307PubMedGoogle Scholar
Rimer, BK, Schildkraut, JM, Lerman, C, Lin, TH, Audrain, J 1996Participation in a women’s breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer ConsortiumCancer7723482355CrossRefPubMedGoogle Scholar
Lerman, C, Trock, B, Rimer, BK, Boyce, A, Jepson, C, Engstrom, PF 1991Psychological and behavioral implications of abnormal mammogramsAnn Intern Med114657661PubMedGoogle Scholar
Dillman, DA 1978Mail and Telephone Surveys: The Total Design MethodWileyNew YorkGoogle Scholar
Stacey, D, O’Connor, AM, DeGrasse, C, Verma, S 2003Development and evaluation of a breast cancer prevention decision aid for higher-risk womenHealth Expect6318CrossRefPubMedGoogle Scholar
Zimmermann, C, Baldo, C, Molino, A 2000Framing of outcome and probability of recurrence: breast cancer patients’ choice of adjuvant chemotherapy (ACT) in hypothetical patient scenariosBreast Cancer Res Treat60914CrossRefPubMedGoogle Scholar
Levine, MN, Gafni, A, Markham, B, MacFarlane, D 1992A bedside decision instrument to elicit a patient’s preference concerning adjuvant chemotherapy for breast cancerAnn Intern Med1175358PubMedGoogle Scholar
McQuellon, RP, Muss, HB, Hoffman, SL, Russell, G, Craven, B, Yellen, SB 1995Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancerJ Clin Oncol13858868PubMedGoogle Scholar
O’Connor, AM, Boyd, NF, Warde, P, Stolbach, L, Till, JE 1987Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferencesJ Chronic Dis40811818CrossRefPubMedGoogle Scholar
Yellen, SB, Cella, DF, Leslie, WT 1994Age and clinical decision making in oncology patientsJ Natl Cancer Inst8617661770PubMedGoogle Scholar
Veronesi, A, Pizzichetta, MA, Ferlante, MA, Zottar, M, Magri, MD, Crivellari, D, Foladore, S 1998Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatmentTumori84372375PubMedGoogle Scholar
Tangrea, JA 1997Patient participation and compliance in cancer chemoprevention trials: issues and concernsProc Soc Exp Biol Med216260265PubMedGoogle Scholar